This is an aggregated industry headline. Read the full story at FierceBiotech →
United Therapeutics pays $140M for thymic cell therapy startup
United Therapeutics has paid $140 million to buy Thymmune Therapeutics for preclinical regenerative cell therapies focused on the thymus.
By FierceBiotech
· Jul 5, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Contract manufacturing powerhouse Lonza is growing in more ways than one. The Swiss company revealed this week…
The WeekBriefing
China’s approval of a CAR‑T for solid tumors breaks a scientific barrier and raises pressure on U.S. developer…
The WeekFiercePharma ↗
Nominate up-and-coming early-career pharma marketing pros here to be featured in Fierce's "Rising Stars" Q&…